

EMAGIN CORP
Form 10-Q
November 13, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

R QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014
or

£ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-15751

eMAGIN CORPORATION

(Exact name of registrant as specified in its charter)

Delaware **56-1764501**
*(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)*

3006 Northup Way, Suite 103, Bellevue, Washington 98004

(Address of principal executive offices)

(425) 284-5200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act) Yes ☐ No ☐

The number of shares of common stock outstanding as of October 31, 2014 was 25,022,875.

Table of Contents

eMagin Corporation

Form 10-Q

For the Quarter ended September 30, 2014

Table of Contents

| | Page |
|--|-------------|
| PART I FINANCIAL INFORMATION | |
| Item 1 <u>Condensed Consolidated Financial Statements</u> | |
| <u>Condensed Consolidated Balance Sheets as of September 30, 2014 (unaudited) and December 31, 2013</u> | 3 |
| <u>Condensed Consolidated Statements of Operations for the Three and Nine Months ended</u> | 4 |
| <u>September 30, 2014 and 2013 (unaudited)</u> | |
| <u>Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2014 and 2013 (unaudited)</u> | 5 |
| <u>Notes to Condensed Consolidated Financial Statements (unaudited)</u> | 6 |
| Item 2 <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 12 |
| Item 3 <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 17 |
| Item 4 <u>Controls and Procedures</u> | 18 |
| PART II OTHER INFORMATION | |
| Item 1 <u>Legal Proceedings</u> | 18 |
| Item 1A <u>Risk Factors</u> | 18 |
| Item 2 <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 18 |
| Item 3 <u>Defaults Upon Senior Securities</u> | 18 |
| Item 4 <u>Mine Safety Disclosures</u> | 18 |
| Item 5 <u>Other Information</u> | 18 |

Item 6 Exhibits

19

SIGNATURES

CERTIFICATIONS

2

Table of Contents**ITEM 1. Condensed Consolidated Financial Statements****eMAGIN CORPORATION****CONDENSED CONSOLIDATED BALANCE SHEETS****(In thousands, except share data)**

| | September 30, 2014 (unaudited) | December 31, 2013 |
|--|--------------------------------------|----------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 4,711 | \$4,032 |
| Investments | 1,250 | 6,250 |
| Accounts receivable, net | 4,407 | 4,319 |
| Inventories, net | 5,529 | 3,434 |
| Prepaid expenses and other current assets | 907 | 745 |
| Total current assets | 16,804 | 18,780 |
| Long-term investments | — | 750 |
| Equipment, furniture and leasehold improvements, net | 9,281 | 9,119 |
| Other assets | 395 | 27 |
| Total assets | \$ 26,480 | \$28,676 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$ 1,278 | \$1,470 |
| Accrued expenses | 2,251 | 2,812 |
| Other current liabilities | 624 | 395 |
| Total current liabilities | 4,153 | 4,677 |
| Commitments and contingencies (Note 8) | | |
| Shareholders' equity: | | |
| Preferred stock, \$.001 par value: authorized 10,000,000 shares: | | |
| Series B Convertible Preferred stock, (liquidation preference of \$5,659,000) stated value \$1,000 per share, \$.001 par value: 10,000 shares designated and 5,659 issued and outstanding as of September 30, 2014 and December 31, 2013 | — | — |
| Common stock, \$.001 par value: authorized 200,000,000 shares, issued and outstanding, 25,022,875 shares as of September 30, 2014 and 23,928,619 as of December 31, 2013 | 25 | 24 |

Edgar Filing: EMAGIN CORP - Form 10-Q

| | | |
|---|------------|-----------|
| Additional paid-in capital | 228,080 | 226,051 |
| Accumulated deficit | (205,278) | (201,576) |
| Treasury stock, 162,066 shares as of September 30, 2014 and December 31, 2013 | (500) | (500) |
| Total shareholders' equity | 22,327 | 23,999 |
| Total liabilities and shareholders' equity | \$ 26,480 | \$ 28,676 |

See notes to Condensed Consolidated Financial Statements.

Table of Contents**eMAGIN CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(In thousands, except share and per share data)****(unaudited)**

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Revenue: | | | | |
| Product | \$5,170 | \$5,770 | \$18,385 | \$20,671 |
| Contract | 529 | 559 | 609 | 1,189 |
| Total revenue, net | 5,699 | 6,329 | 18,994 | 21,860 |
| Cost of goods sold: | | | | |
| Product | 3,645 | 3,848 | 12,814 | 12,821 |
| Contract | 309 | 256 | 335 | 672 |
| Total cost of goods sold | 3,954 | 4,104 | 13,149 | 13,493 |
| Gross profit | 1,745 | 2,225 | 5,845 | 8,367 |
| Operating expenses: | | | | |
| Research and development | 957 | 1,239 | 3,665 | 3,882 |
| Selling, general and administrative | 1,819 | 2,041 | 5,869 | 6,358 |
| Total operating expenses | 2,776 | 3,280 | 9,534 | 10,240 |
| (Loss) income from operations | (1,031 |) (1,055 |) (3,689 |) (1,873 |
| Other income (expense): | | | | |
| Interest expense, net | (11 |) (11 |) (32 |) (32 |
| Other income, net | 6 | 9 | 20 | 45 |
| Total other income (expense), net | (5 |) (2 |) (12 |) 13 |
| (Loss) income before provision for income taxes | (1,036 |) (1,057 |) (3,701 |) (1,860 |
| Provision for income taxes | — | 3,502 | — | 3,502 |
| Net (loss) income | \$(1,036 |) \$(4,559 |) \$(3,701 |) \$(5,362 |
| (Loss) income per share, basic | \$(0.04 |) \$(0.19 |) \$(0.15 |) \$(0.23 |
| (Loss) income per share, diluted | \$(0.04 |) \$(0.19 |) \$(0.15 |) \$(0.23 |

Edgar Filing: EMAGIN CORP - Form 10-Q

Weighted average number of shares outstanding:

| | | | | |
|---------|------------|------------|------------|------------|
| Basic | 24,842,945 | 23,718,106 | 24,187,285 | 23,610,531 |
| Diluted | 24,842,945 | 23,718,106 | 24,187,285 | 23,610,531 |

See notes to Condensed Consolidated Financial Statements.

Table of Contents**eMAGIN CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands)**

| | Nine Months Ended September 30, 2014 (unaudited) | 2013 |
|---|---|-------------|
| Cash flows from operating activities: | | |
| Net loss | \$ (3,701) | \$ (5,362) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | | |
| Depreciation and amortization | 863 | 656 |
| Reduction in provision for doubtful accounts | (28) | (1) |
| Amortization of bond premium | — | 20 |
| Inventory reserve | 134 | 16 |
| Stock-based compensation | 884 | 1,645 |
| Loss (gain) on sale of asset | 8 | (9) |
| Deferred income taxes | — | 3,499 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (60) | 1,305 |
| Inventories, net | (2,230) | (1,200) |
| Prepaid expenses and other current assets | (243) | (568) |
| Accounts payable, accrued expenses, and other current liabilities | (764) | 113 |
| Net cash (used in) provided by operating | (5,137) | 114 |

activities

Cash flows from

investing activities:

| | | |
|-----------------------|----------|--------|
| Purchase of equipment | (1,037) | (757) |
|-----------------------|----------|--------|

| | | |
|-----------------------------|---|----|
| Proceeds from sale of asset | 8 | 15 |
|-----------------------------|---|----|

| | | |
|-------------------------|-------|---|
| Purchase of intangibles | (50) | — |
|-------------------------|-------|---|

| | | |
|---------------------------|-------|--------|
| Maturities of investments | 7,750 | 11,250 |
|---------------------------|-------|--------|

| | | |
|-------------------------|----------|-----------|
| Purchase of investments | (2,000) | (10,500) |
|-------------------------|----------|-----------|

| | | |
|---|-------|---|
| Net cash provided by investing activities | 4,671 | 8 |
|---|-------|---|

Cash flows from

financing activities:

| | | |
|--|-------|-----|
| Proceeds from exercise of stock options and warrants | 1,145 | 340 |
|--|-------|-----|

| | | |
|----------------------------|---|-------|
| Purchase of treasury stock | — | (36) |
|----------------------------|---|-------|

| | | |
|---|-------|-----|
| Net cash provided by financing activities | 1,145 | 304 |
|---|-------|-----|

| | | |
|---|-----|-----|
| Net increase in cash and cash equivalents | 679 | 426 |
|---|-----|-----|

| | | |
|--|-------|-------|
| Cash and cash equivalents, beginning of period | 4,032 | 4,385 |
|--|-------|-------|

| | | |
|--|----------|----------|
| Cash and cash equivalents, end of period | \$ 4,711 | \$ 4,811 |
|--|----------|----------|

| | | |
|------------------------|------|------|
| Cash paid for interest | \$ 9 | \$ 9 |
|------------------------|------|------|

| | | |
|---------------------|------|-------|
| Cash paid for taxes | \$ — | \$ 72 |
|---------------------|------|-------|

Non-cash investing activities:

| | | |
|-----------------------------|--------|------|
| Intangible assets - patents | \$ 240 | \$ — |
|-----------------------------|--------|------|

See notes to Condensed Consolidated Financial Statements.

Table of Contents

eMAGIN CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1: Summary of Significant Accounting Policies

The Business

eMagin Corporation (the “Company”) designs, develops, manufactures, and markets OLED (organic light emitting diode) on silicon microdisplays and virtual imaging products which utilize OLED microdisplays. The Company’s products are sold mainly in North America, Asia, and Europe.

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements of eMagin Corporation and its subsidiary reflect all adjustments, including normal recurring accruals, necessary for a fair presentation. All significant intercompany balances and transactions have been eliminated in consolidation. Certain information and footnote disclosure normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the Securities and Exchange Commission. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the period ended September 30, 2014 are not necessarily indicative of the results to be expected for the full year. The consolidated condensed financial statements of December 31, 2013 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

In accordance with accounting principles generally accepted in the United States of America, management utilizes certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments related to, among others, allowance for doubtful accounts, warranty reserves, inventory reserves, stock-based compensation expense, deferred tax asset valuation allowances, litigation and other loss contingencies. Management bases its estimates and judgments on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the

basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue and Cost Recognition

Revenue on product sales is recognized when persuasive evidence of an arrangement exists, such as when a purchase order or contract is received from the customer, the price is fixed, title and risk of loss to the goods has changed and there is a reasonable assurance of collection of the sales proceeds. We obtain written purchase authorizations from our customers for a specified amount of product at a specified price and consider delivery to have occurred at the time of shipment.

Revenues from research and development activities relating to firm fixed-price contracts and cost-type contracts are generally recognized on the percentage-of-completion method of accounting as costs are incurred (cost-to-cost basis). Progress is generally based on a cost-to-cost approach however an alternative method may be used such as physical progress, labor hours or others depending on the type of contract. Physical progress is determined as a combination of input and output measures as deemed appropriate by the circumstances. Contract costs include all direct material, labor and subcontractor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party.

New Accounting Pronouncement

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU 2014-09 will be effective for the Company beginning January 1, 2017. Early adoption is not permitted. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the impact of adopting the new revenue standard on its consolidated financial statements.

Table of Contents

Investments

Investments consist of FDIC-insured certificates of deposit (“CDs”) which are classified as held-to-maturity since the Company has the positive intent and ability to hold them until maturity. The CDs are carried at cost which approximates fair value. As of September 30, 2014, the investments mature within one year.

Intangible Assets – Patents

Acquired patents are recorded at purchase price as of the date acquired and amortized over the expected useful life which is generally the remaining life of the patent.

In September 2014, the Company purchased several patents for \$290,000. The Company will amortize the acquired patents over their remaining useful life. As of September 30, 2014, the weighted average remaining useful life of these patents was approximately 7.1 years. The Company did not record any amortization expense related to these patents for the three and nine months ended September 30, 2014. The estimated amortization expense related to the acquired patents for the remainder of 2014 will be \$13 thousand and for future years, \$50 thousand annually.

Product warranty

The Company offers a one-year product replacement warranty. In general, the standard policy is to repair or replace the defective products. The Company accrues for estimated returns of defective products at the time revenue is recognized based on historical activity as well as for specific known product issues. The determination of these accruals requires the Company to make estimates of the frequency and extent of warranty activity and estimate future costs to replace the products under warranty. If the actual warranty activity and/or repair and replacement costs differ significantly from these estimates, adjustments to cost of revenue may be required in future periods.

The following table provides a summary of the activity related to the Company's warranty liability included in other current liabilities, (in thousands):

| Three Months Ended September 30, (unaudited) | | Nine Months Ended September 30, (unaudited) | |
|---|------|--|------|
| 2014 | 2013 | 2014 | 2013 |

Edgar Filing: EMAGIN CORP - Form 10-Q

| | | | | |
|---------------------------------------|--------|--------|-------|-------|
| Warranty accrual, beginning of period | \$ 603 | \$ 288 | \$394 | \$276 |
| Provision for warranty costs | 69 | 78 | 586 | 259 |
| Warranty expenditures | (49) | (60) | (357) | (229) |
| Warranty accrual, end of period | \$ 623 | \$ 306 | \$623 | \$306 |

Net (Loss) Income per Common Share

Basic (loss) income per share is computed using the weighted average number of common shares outstanding during the period, and excludes any dilutive effects of common stock equivalent shares, such as stock options, warrants, and convertible preferred stock. Diluted (loss) income per share is computed using the weighted average number of common shares outstanding and potentially dilutive common stock equivalent shares outstanding during the period. Common stock equivalent shares are excluded from the computation if their effect is anti-dilutive.

The Company's Series B Convertible Preferred stock ("Preferred Stock – Series B") is considered a participating security as the preferred stock participates in dividends with the common stock, which requires the use of the two-class method when computing basic and diluted earnings per share. The Preferred Stock – Series B is not required to absorb any net loss. Though the Company paid a one-time special dividend in 2012, the Company does not expect to continue to pay dividends on its common or preferred stock in the near future.

For the three and nine months ended September 30, 2014 and 2013, the Company reported a net loss and as a result, basic and diluted net loss per common share are the same. Therefore, in calculating net loss per share amounts, shares underlying the potentially dilutive common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive.

Table of Contents

The following is a table of the potentially dilutive common stock equivalents for the three and nine month periods ended September 30, 2014 and 2013 that were not included in diluted EPS as their effect would be anti-dilutive:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Options | 4,750,093 | 5,637,319 | 4,750,093 | 5,637,319 |
| Convertible preferred stock | 7,545,333 | 7,545,333 | 7,545,333 | 7,545,333 |
| Total potentially dilutive common stock equivalents | 12,295,426 | 13,182,652 | 12,295,426 | 13,182,652 |

Note 2: Accounts Receivable, net

The majority of the Company's commercial accounts receivable are due from Original Equipment Manufacturers ("OEM's"). Credit is extended based on an evaluation of a customer's financial condition and, generally, collateral is not required.

Accounts receivable consisted of the following (in thousands):

| | September 30, 2014 (unaudited) | December 31, 2013 |
|--------------------------------------|---|-------------------------|
| Accounts receivable | \$ 4,524 | \$ 4,464 |
| Less allowance for doubtful accounts | (117) | (145) |
| Net receivable | \$ 4,407 | \$ 4,319 |

Note 3: Inventories, net

The components of inventories are as follows (in thousands):

| September 30, | December 31, |
|------------------|-----------------|
|------------------|-----------------|

| | 2014 (unaudited) | 2013 |
|------------------------|---------------------|----------|
| Raw materials | \$ 2,620 | \$ 1,905 |
| Work in process | 1,481 | 987 |
| Finished goods | 1,657 | 637 |
| Total inventories | 5,758 | 3,529 |
| Less inventory reserve | (229) | (95) |
| Total inventories, net | \$ 5,529 | \$ 3,434 |

Note 4: Line of Credit

On September 1, 2014, the Company renewed its credit facility with Access Business Finance, LLC (“Access”) under which the Company may borrow up to a maximum of \$3 million based on a borrowing base equivalent of 75% of eligible accounts receivable. The terms are: interest rate is Prime plus 4% but not less than 7.25%, the minimum monthly interest payment is \$1,000 and the early termination fee is \$6,000. The renewal date of the line of credit is September 1, 2015. The Company’s obligations under the credit facility are secured by its assets. For the nine months ended September 30, 2014, the Company had not borrowed on its line of credit.

Note 5: Stock-based Compensation

The Company uses the fair value method of accounting for share-based compensation arrangements. The fair value of stock options is estimated at the date of grant using the Black-Scholes option valuation model. Stock-based compensation expense is reduced for estimated forfeitures and is amortized over the vesting period using the straight-line method.

Table of Contents

The following table summarizes the allocation of non-cash stock-based compensation to our expense categories for the three and nine month periods ended September 30, 2014 and 2013 (in thousands):

| | Three Months Ended September 30, (unaudited) | | Nine Months Ended September 30, (unaudited) | |
|-------------------------------------|--|-------|---|---------|
| | 2014 | 2013 | 2014 | 2013 |
| Cost of revenue | \$28 | \$68 | \$131 | \$219 |
| Research and development | 38 | 137 | 223 | 428 |
| Selling, general and administrative | 168 | 363 | 530 | 998 |
| Total stock compensation expense | \$234 | \$568 | \$884 | \$1,645 |

At September 30, 2014, total unrecognized compensation costs related to stock options was approximately \$0.6 million, net of estimated forfeitures. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures and is expected to be recognized over a weighted average period of approximately 1.6 years.

The following key assumptions were used in the Black-Scholes option pricing model to determine the fair value of stock options granted:

| | For the Nine Months Ended September 30, | | | |
|--------------------------|---|---|--------------|---|
| | 2014 | | 2013 | |
| Dividend yield | 0 | % | 0 | % |
| Risk free interest rates | 0.78 – 1.85 | % | 0.35 - 1.48 | % |
| Expected volatility | 59.1 to 67.8 | % | 67.6 to 73.8 | % |
| Expected term (in years) | 3.25 to 5.0 | | 3.5 to 5.0 | |

The Company does not expect to pay dividends in the near future therefore the Company used an expected dividend yield of 0%. The risk-free interest rate used in the Black-Scholes option pricing model is based on the implied yield at the time of grant available on U.S. Treasury securities with an equivalent term. Expected volatility is based on the weighted average historical volatility of the Company's common stock for the equivalent term. The expected term of options represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience and vesting schedules of similar awards.

Edgar Filing: EMAGIN CORP - Form 10-Q

A summary of the Company's stock option activity for the nine months ended September 30, 2014 is presented in the following table (unaudited):

| | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (In Years) | Aggregate Intrinsic Value |
|--|---------------------|--|---|--|
| Outstanding at December 31, 2013 | 4,597,186 | \$ 3.82 | | |
| Options granted | 404,113 | 2.63 | | |
| Options exercised | (94,256) | 1.22 | | |
| Options forfeited | (95,727) | 3.88 | | |
| Options cancelled or expired | (61,223) | 6.10 | | |
| Outstanding at September 30, 2014 | 4,750,093 | \$ 3.74 | 4.04 | \$1,578,581 |
| Vested or expected to vest at September 30, 2014 (1) | 4,732,437 | \$ 3.75 | 4.04 | \$1,577,820 |
| Exercisable at September 30, 2014 | 4,308,740 | \$ 3.77 | 3.98 | \$1,559,561 |

(1) The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total unvested options.

Table of Contents

The aggregate intrinsic value in the table above represents the difference between the exercise price of the underlying options and the quoted price of the Company's common stock. For the three and nine months ended September 30, 2014, the aggregate intrinsic value of options exercised was approximately \$27 thousand and \$120 thousand, respectively. The Company issues new shares of common stock upon exercise of stock options.

Note 6: Shareholders' Equity

Preferred Stock - Series B Convertible Preferred Stock ("the Preferred Stock – Series B")

As of September 30, 2014 and December 31, 2013, there were 5,659 shares of Preferred Stock – Series B issued and outstanding.

Common Stock

The Company received approximately \$44 thousand and \$115 thousand for the exercise of 26,893 and 94,256 stock options in the three and nine months ended September 30, 2014, respectively. The Company received approximately \$83 thousand and \$340 thousand for the exercise of 40,144 and 203,759 stock options in the three and nine months ended September 30, 2013, respectively. In the three and nine months ended September 30, 2014, the Company received approximately \$1.0 million for the exercise of 1 million warrants. There was no warrant activity in the nine months ended September 30, 2013.

Note 7: Income Taxes

The Company's effective tax rate is calculated quarterly based upon current assumptions relating to the full year's estimated operating results and various tax-related items. The Company's effective tax rate for the nine month period ended September 30, 2014 was 0% as compared to (103.8)% for the nine months ended September 30, 2013. The difference between the effective tax rate of 0% and the U.S. federal statutory rate of 34% for the nine months ended September 30, 2014 was primarily due to recognizing a full valuation allowance on deferred tax assets. The difference between the effective tax rate of (103.8)% and the U.S. federal statutory rate of 34% for the nine months ended September 30, 2013 was primarily due to the change in the valuation allowance on deferred tax assets.

At December 31, 2013, the Company determined that based on all available evidence, both positive and negative, and based on the weight of the available evidence, including the Company's 2013 operating loss and projected cumulative loss through 2014, it was more likely than not that none of its deferred tax assets would be realized and therefore, recorded a full valuation allowance. As the Company incurred an operating loss for the three month period ended September 30, 2014 and is still projecting a cumulative loss through 2014, it is still more likely than not that none of

its deferred tax assets would be realized and therefore, the Company continued to record a full valuation allowance. The Company's net operating loss carry forward amounts substantially expire in 2028.

Due to the Company's operating loss carryforwards, all tax years remain open to examination by the major taxing jurisdictions to which the Company is subject. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense.

Note 8: Commitments and Contingencies

Operating Leases

The Company leases office facilities and office, lab and factory equipment under operating leases. Certain leases provide for payments of monthly operating expenses. The Company currently has lease commitments for space in Hopewell Junction, New York, Bellevue, Washington, and Santa Clara, California.

The Company's manufacturing facilities are leased from IBM in Hopewell Junction, New York. The Company leases approximately 37,000 square feet to house its equipment for OLED microdisplay fabrication and for research and development, an assembly area and administrative offices. The lease expires May 31, 2019. The administrative offices are located in Bellevue, Washington where the current lease expired on August 31, 2014 and the Company negotiated a new month-to-month lease for approximately 1,500 square feet effective September 1, 2014. Effective July 1, 2014, the Company has a new lease for approximately 1,800 square feet of office space for design and product development in Santa Clara, California with the lease expiring October 31, 2015.

Rent expense was approximately \$253 thousand and \$842 thousand, respectively, for the three and nine months ended September 30, 2014 and approximately \$303 thousand and \$909 thousand, respectively, for the three and nine months ended 2013.

Table of Contents***Equipment Purchase Commitments***

The Company has committed to equipment purchases of approximately \$0.5 million at September 30, 2014.

Note 9: Concentrations

For the three and nine months ended September 30, 2014, approximately 51% and 47%, respectively, of the Company's net revenues were derived from customers in the United States and approximately 49% and 53%, respectively, of the Company's net revenues were derived from international customers. For the three and nine months ended September 30, 2013, approximately 55% and 61%, respectively, of the Company's net revenues were derived from customers in the United States and approximately 45% and 39%, respectively, of the Company's net revenues were derived from international customers. For the three months ended September 30, 2014, there were two customers that accounted for 23% and for the nine months ended September 30, 2014, there was one customer that accounted for 10% of its net revenue. For the three and nine months ended September 30, 2013, one customer accounted for 11% and 13%, respectively, of its net revenue. As of September 30, 2014, one customer accounted for 31% of its accounts receivable.

The following is a schedule of revenue by geographic location (in thousands):

| | Three Months Ended September 30, (unaudited) | | Nine Months Ended September 30, (unaudited) | |
|---------------------------------|---|---------|--|-----------|
| | 2014 | 2013 | 2014 | 2013 |
| North and South America | \$3,003 | \$3,469 | \$ 9,304 | \$ 13,808 |
| Europe, Middle East, and Africa | 1,846 | 2,004 | 7,368 | 6,017 |
| Asia Pacific | 850 | 856 | 2,322 | 2,035 |
| Total | \$5,699 | \$6,329 | \$ 18,994 | \$ 21,860 |

The Company purchases principally all of its silicon wafers from a single supplier located in Taiwan.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Statement of Forward-Looking Information

In this quarterly report, references to "eMagin Corporation," "eMagin," "Virtual Vision," "the Company," "we," "us," and "our" refer to eMagin Corporation and its wholly owned subsidiary, Virtual Vision, Inc.

Except for the historical information contained herein, some of the statements in this Report contain forward-looking statements that involve risks and uncertainties. These statements are found in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors." They include statements concerning: our business strategy; expectations of market and customer response; liquidity and capital expenditures; future sources of revenues; expansion of our proposed product line; and trends in industry activity generally. In some cases, you can identify forward-looking statements by words such as "may," "will," "should," "expect," "plan," "could," "anticipate," "intend," "believe," "estimate," "predict," "potential," "goal," or "continue" or similar terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the risks outlined under "Risk Factors," that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. For example, assumptions that could cause actual results to vary materially from future results include, but are not limited to: our ability to successfully develop and market our products to customers; our ability to successfully implement resolutions related to customer stop orders; our ability to generate customer demand for our products in our target markets; the development of our target markets and market opportunities; our ability to manufacture suitable products at competitive cost; our ability to successfully launch new equipment on our manufacturing line; market pricing for our products and for competing products; the extent of increasing competition; technological developments in our target markets and the development of alternate, competing technologies in them; and sales of shares by existing shareholders. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Unless we are required to do so under federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.

Overview

In the third quarter, eMagin continued deliveries of our display products to over 71 different customers worldwide and performed R&D contract services for 6 customers. We received \$6.8 million of new R&D contract awards. Our team completed the install of equipment for producing ultra-high brightness direct-patterned displays, we made improvements to the clean room and we performed scheduled maintenance on both of our OLED deposition tools which had been overdue. These were important accomplishments but resulted in fewer production days which impacted revenues. We also had a couple customers delay delivery dates which postponed revenue to fourth quarter.

Our new OLED deposition tool continued to provide improved uptime and throughput (except for the scheduled maintenance period in the quarter). Investments continued in developing new processes that provide ultra-high brightness displays, an important attribute for applications that are used in direct sunlight or daylight such as wearable personal headsets and avionic head mounted displays (“HMDs”). Our technical team successfully produced ultra-high resolution prototype displays that are now being demonstrated to potential customers. Our team is also developing an HMD for virtual reality that we believe will provide some significant advantages over other HMDs currently on the market or known to us to exist.

We continue to work through some items associated with the first quarter 2014 stop ship event with three of our customers. A stop ship order essentially delays product shipments until the particular issue(s) are resolved with the customer. For the first customer, shipments resumed in Q2 with no expected loss of revenue. Shipments to the second customer have resumed with the delivery of parts using a modified manufacturing process for qualification and test by our customer. Qualification of these displays was successfully completed both at eMagin and by our customer in Q3. Production is resuming with no loss of overall volume, but with some shipments originally scheduled for 2014 extending into 2015. For the third customer, we have delivered a product with a different packaging design that has successfully completed eMagin’s internal qualification process and that better meets our customer’s needs. Once our customer completes its qualification of those parts in its system, we expect deliveries to begin in 2015.

As a result of the status of the business, our improved R&D contract outlook and demand for our state-of-the-art microdisplays, we reaffirm our previous guidance that we anticipate the last three quarters of 2014 will have higher average revenue than Q1 2014.

Financial Results

In the third quarter, revenues reflected a scheduled manufacturing line maintenance period which resulted in significantly fewer days of production in the quarter. We also had a couple customers delay delivery dates which postponed revenue to fourth quarter. We produced fewer units and display shipments were lower resulting in decreased total revenues of \$5.7 million compared to \$6.3 million in third quarter last year. Gross margin was 31% compared to 35% same quarter last year and 31% last quarter. The decrease in gross margin from third quarter last year was the result of lower volume and lower yield. We were able to sustain the improvement we saw in first and second quarter gross margin over fourth quarter 2013 despite the lower volume due to a higher average selling price, improved manufacturing expense controls and better yield. Operating expenses also decreased, to \$2.8 million in third quarter from \$3.2 million in second quarter and \$3.3 million in third quarter last year. The resulting operating loss narrowed to \$1.0 million in the third quarter 2014 from \$1.1 million in the third quarter of 2013.

Table of Contents

New Business

In addition to the major Government R&D awards (\$6.8M) announced in Q3, we have delivered or taken orders for prototypes of our new Digital SVGA and SXGA096 displays from major global customers who have selected or are considering these displays for upcoming new products. We have also seen increasing interest in all of our high brightness displays, and have delivered or booked orders for prototype high and ultrahigh brightness color and monochrome (XLS, ULT, and XLT) displays, confirming that these displays offer advantages for applications that use low efficiency optical systems or must provide augmented reality in the daytime such as avionics and commercial data glasses applications. We also have booked a number of small development/R&D contracts from companies investing in eMagin's OLED display technology for proprietary products. In addition, during the quarter we received two major follow on orders from two different long standing customers which will have significant deliveries continuing into 2015.

New Technology Development

During the third quarter significant progress was made towards demonstrating a full color ultra-high brightness OLED microdisplay. A new direct patterning tool was acquired during the second quarter for this purpose. The tool was made operational in the third quarter. Using this tool, a full color WUXGA resolution OLED microdisplay was fabricated. This display was tested and demonstrated to a few select potential customers. The maximum luminance achieved was 7,000 nits, which is the highest brightness ever for an OLED display of any size or resolution. Also, during the third quarter, three US government grants were awarded to eMagin with a total value in excess of \$6.8 million. These grants are directed towards making the full color high resolution ultra-high brightness OLED microdisplays manufacturable. Upon the completion of the program, eMagin will then produce full color OLED microdisplays that will have brightness in excess of 10,000 cd/m² (3,000 fl) or "nits" with a contrast of at least 10,000:1 and resolutions higher than 1920x1200 pixels. In addition, a highly improved backplane technology will be developed. This advanced backplane will enable significant performance improvements in the OLED device including more than 30% reduction in power consumption compared to the existing OLED backplane technology.

New Product Development

The production qualification of our new DSVGA display was completed in the second quarter. We began shipping production quantities of the DSVGA in Q3. This display is targeted to replace the long-running SVGA+ display with our latest digital technology and product improvements. First prototypes of our SXGA096 product are scheduled to be available by the end of fourth quarter. The SXGA096 will provide the high resolution on a SXGA display but with a smaller form factor and lower cost of production than larger pixel SXGA displays.

We are developing an Immersive Head Mounted Display ("IHMD") headset. This IHMD incorporates eMagin's latest high-resolution OLED micro-displays and patented optics and enables a paradigm shift in the look and performance of our Virtual Reality ("VR") HMD. The OLED microdisplay is the fundamental reason that eMagin's IHMD is half the weight and size of its VR HMD counter parts. We have taken a non-traditional approach which results in a radically

different form factor. The field of view (“FOV”) exceeds one hundred degrees and can have resolutions ranging from one mega pixels per eye (“MP/eye”) to four MP/eye. The IHMD incorporates proprietary features not found on other VR HMDs such as a “flip-up” viewer capability. The first prototype is expected to be completed at the end of 2014 and will have a resolution of 4MP/eye, nearly 4 times that of other VR HMDs known to us. We believe there are a wide range of VR applications for this IHMD from gaming, medical, architecture, and 3D design to education and military training and simulation. This first product will target the high-end gaming market. This is the latest HMD in a line of systems developed by eMagin that began with our Z-800 launched in mid-2005 that received the Consumer Electronics Show (CES) Innovations award for Best New Display and Best New Gaming Device for 2006.

At October 31, 2014, we had a total of 82 employees, of which 78 were full-time employees as compared to a total of 111 employees, of which 107 were full-time employees at December 31, 2013.

A detailed discussion of our business may be found in Part I, “Business,” of our 2013 Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 13, 2014.

Table of Contents

CRITICAL ACCOUNTING POLICIES

Revenue and Cost Recognition

Revenue on product sales is recognized when persuasive evidence of an arrangement exists, such as when a purchase order or contract is received from the customer, the price is fixed, title and risk of loss to the goods has changed and there is a reasonable assurance of collection of the sales proceeds. We obtain written purchase authorizations from our customers for a specified amount of product at a specified price and consider delivery to have occurred at the time of shipment.

Revenues from research and development activities relating to firm fixed-price contracts and cost-type contracts are generally recognized on the percentage-of-completion method of accounting as costs are incurred (cost-to-cost basis). Progress is generally based on a cost-to-cost approach however an alternative method may be used such as physical progress, labor hours or others depending on the type of contract. Physical progress is determined as a combination of input and output measures as deemed appropriate by the circumstances. Contract costs include all direct material, labor and subcontractor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party.

Intangible Assets – Patents

Acquired patents are recorded at purchase price as of the date acquired and amortized over the expected useful life which is generally the remaining life of the patent. In September 2014, we purchased several patents for \$290,000 which will be amortized over their remaining useful life. As of September 30, 2014, the weighted average remaining useful life of these patents was approximately 7.1 years.

Income Taxes

Our deferred tax assets and their potential realizability are evaluated each quarter to determine if any changes should be made to the valuation allowance. At December 31, 2013, we determined that based on all available evidence, both positive and negative, and based on the weight of the available evidence, including our 2013 operating loss and projected cumulative loss through 2014, it was more likely than not that none of our deferred tax assets would be realized and therefore, recorded a full valuation allowance. As we incurred an operating loss for the nine month period ended September 30, 2014 and are still projecting a cumulative loss through 2014, it is still more likely than not that none of our deferred tax assets would be realized and therefore, we continued to record a full valuation allowance.

Other critical accounting policies, as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, relate to product warranty, use of estimates, fair value of financial instruments and stock-based compensation, and additional information on accounting for income taxes.

RESULTS OF OPERATIONS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 COMPARED TO THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2013

Revenues

| | Three Months Ended September 30, 2014 2013 Change (unaudited) (in thousands) | | | Nine Months Ended September 30, (unaudited) (in thousands) | | |
|--------------------|--|---------|-----------|---|----------|-----------|
| Product | \$5,170 | \$5,770 | \$ (600) | \$18,385 | \$20,671 | \$(2,286) |
| Contract | \$529 | \$559 | \$ (30) | \$609 | \$1,189 | \$(580) |
| Total revenue, net | \$5,699 | \$6,329 | \$ (630) | \$18,994 | \$21,860 | \$(2,866) |

Revenues for the three and nine months ended September 30, 2014 were approximately \$5.7 million and \$19.0 million, respectively, as compared to approximately \$6.3 million and \$21.9 million, respectively, for the three and nine months ended September 30, 2013.

Table of Contents

Product revenue is comprised primarily of sales of displays, as well as sales of other hardware. For the three months ended September 30, 2014, product revenue decreased approximately \$0.6 million or 10% as compared to the three months ended September 30, 2013. The revenue decrease was primarily due to fewer units shipped, partially offset by an increase in the average selling price per unit. Fewer days of production due to scheduled maintenance on the manufacturing line in the quarter was the primary cause of the lower output and fewer units shipped. We also had a couple customers delay delivery dates which postponed revenue to fourth quarter. For the nine months ended September 30, 2014, product revenue decreased \$2.3 million or 11% as compared to the nine months ended September 30, 2013. The revenue decrease was primarily due to fewer units shipped, partially offset by an increase in the average selling price per unit.

Contract revenue is comprised of revenue from research and development (“R&D”) or non-recurring engineering (“NRE”) contracts. For the three and nine months ended September 30, 2014, contract revenue decreased approximately \$0.03 million and \$0.6 million, respectively, as compared to the three months and nine months ended September 30, 2013. The decreases in the R&D contract revenue for both the three and nine months were primarily due to fewer active R&D contracts and less contract work completed during each period.

Cost of Goods Sold

| | Three Months Ended September 30, | | | Nine Months Ended September 30, | | |
|--------------------------|---|---------|-----------|--|----------|-----------|
| | 2014 | 2013 | Change | 2014 | 2013 | Change |
| | (unaudited) | | | (unaudited) | | |
| | (in thousands) | | | (in thousands) | | |
| Product | \$3,645 | \$3,848 | \$ (203) | \$12,814 | \$12,821 | \$ (7) |
| Contract | \$309 | \$256 | \$ 53 | \$335 | \$672 | \$ (337) |
| Total cost of goods sold | \$3,954 | \$4,104 | \$ (150) | \$13,149 | \$13,493 | \$ (344) |

Cost of goods sold is comprised of costs of product and contract revenues. Cost of product revenue includes materials, labor and manufacturing overhead, warranty costs and depreciation related to our products. Cost of contract revenue includes direct and allocated indirect costs associated with performance of contracts. Cost of goods sold for the three and nine month period ended September 30, 2014 as compared to the three and nine month period ended September 30, 2013 decreased \$0.2 million and \$0.3 million, respectively. Cost of goods sold as a percentage of revenues was 69% for both the three and nine month periods ended September 30, 2014 as compared to 65% and 62%, respectively, for the three and nine month periods ended September 30, 2013. The increase in third quarter 2014 from third quarter last year was due to lower yield, a lower volume of production and decreased revenues. The average cost per display increased in 2014 for both the three and nine month periods. This increase is primarily due to fewer displays produced compared to 2013. In the third quarter 2014, non-material manufacturing costs decreased and yield improved 13% but these improvements were offset by lower unit production resulting in a higher cost per unit.

The following table outlines product, contract and total gross profit and related gross margins for the three and nine months ended September 30, 2014 and 2013 (dollars in thousands):

| | Three Months Ended September 30, 2014 2013 (unaudited) | | | | Nine Months Ended September 30, 2014 2013 (unaudited) | | | |
|-------------------------------|---|---|----------|---|---|---|----------|---|
| Product revenue gross profit | \$ 1,525 | | \$ 1,922 | | \$ 5,571 | | \$ 7,850 | |
| Product revenue gross margin | 29 | % | 33 | % | 30 | % | 38 | % |
| Contract revenue gross profit | \$ 220 | | \$ 303 | | \$ 274 | | \$ 517 | |
| Contract revenue gross margin | 42 | % | 54 | % | 45 | % | 43 | % |
| Total gross profit | \$ 1,745 | | \$ 2,225 | | \$ 5,845 | | \$ 8,367 | |
| Total gross margin | 31 | % | 35 | % | 31 | % | 38 | % |

Table of Contents

The gross profit for the three and nine months ended September 30, 2014 as compared to the three and nine months ended September 30, 2013 decreased approximately \$0.5 million and \$2.5 million, respectively. Gross profit is a function of revenues less cost of goods sold. Revenues decreased from 2013 in both the three and nine month periods. Lower yield and lower production volume increased the cost of goods per display resulting in lower gross profit in both the three and nine month periods. For both the three and nine months ended September 30, 2014, the gross margin was 31% as compared to 35% and 38%, respectively, for the three and nine months ended September 30, 2013.

The product gross profit for the three and nine months ended September 30, 2014 as compared to the three and nine months ended September 30, 2013 decreased approximately \$0.4 million and \$2.3 million, respectively. Product gross margin was 29% and 30%, respectively, for the three and nine months ended September 30, 2014 down from 33% and 38%, respectively, for the three and nine month periods ended September 30, 2013.

The contract gross profit for the three and nine months ended September 30, 2014 as compared to the three and nine months ended September 30, 2013 decreased approximately \$0.08 million and \$0.2 million, respectively. Contract gross margin for the three months ended September 30, 2014 decreased to 42% from 54%, for the same three month period in 2013. Contract gross margin for the nine months ended September 30, 2014 increased to 45% from 43% for the same nine month period in 2013.

Operating Expenses

| | Three Months Ended September 30, 2014 2013 Change | | | Nine Months Ended September 30, 2014 2013 Change | | |
|---|---|---------|-----------|--|----------|-----------|
| | (unaudited) | | | (unaudited) | | |
| | (\$ in thousands) | | | (\$ in thousands) | | |
| Research and development expense | \$957 | \$1,239 | \$ (282) | \$3,665 | \$3,882 | \$ (217) |
| Percentage of net revenue | 17 % | 20 % | | 19 % | 18 % | |
| Selling, general and administrative expense | \$1,819 | \$2,041 | \$ (222) | \$5,869 | \$6,358 | \$ (489) |
| Percentage of net revenue | 32 % | 32 % | | 31 % | 29 % | |
| Total operating expenses | \$2,776 | \$3,280 | \$ (504) | \$9,534 | \$10,240 | \$ (706) |
| Percentage of net revenue | 49 % | 52 % | | 50 % | 47 % | |

Research and Development. Research and development expenses are company-funded and include salaries and related benefits, development materials and other costs specifically allocated to the development of new technologies and microdisplay products, OLED materials and subsystems. R&D related costs associated with fulfilling contracts are categorized as contract cost of goods sold. R&D expenses for the three and nine months ended September 30,

2014 decreased approximately \$0.3 million and \$0.2 million, respectively, 23% and 6%, respectively, as compared to the three and nine months ended September 30, 2013. As a percentage of revenue, Q3 2014 decreased to 17% of revenue as compared to 20% for Q3 2013 and for the year 2014 increased to 19% as compared to 18% for the year 2013. The decrease in company-funded R&D expenses is due to expense being allocated to outside funded contracts, several started in Q3 2014.

Selling, General and Administrative. Selling, general and administrative (“SG&A”) expenses consist principally of salaries and related benefits, professional services fees and marketing, general corporate, and administrative expenses. Selling, general and administrative expenses for the three and nine months ended September 30, 2014 decreased approximately \$0.2 million or 11% and \$0.5 million or 8%, respectively, as compared to the three and nine months ended September 30, 2013. As a percentage of revenue, Q3 2014 and 2013 were both 32% and for the year 2014 increased to 31% as compared to 29% for the year 2013. These decreases in SG&A are due primarily to lower stock-based compensation expense and cost efficiencies implemented during 2014.

Other Income (Expense), net. Other income (expense), net consists primarily of interest income earned on investments, interest expense and gain/loss on sale of assets. For both the three and nine month periods ended September 30, 2014 and 2013, interest expense was approximately \$11 thousand and \$32 thousand, respectively. We have no debt upon which we are incurring interest expense however we pay fees to keep our line of credit available. Other income of which the majority is interest income for the three and nine months ended September 30, 2014 was approximately \$6 thousand and \$20 thousand, respectively, as compared to approximately \$9 thousand and \$45 thousand, respectively, for the three and nine months ended September 30, 2013.

Table of Contents

Liquidity and Capital Resources

We had approximately \$6.0 million of cash, cash equivalents, and investments at September 30, 2014 as compared to approximately \$11.0 million at December 31, 2013. Of the \$6.0 million in cash, approximately \$1.25 million was invested in certificates of deposit (“CDs”).

Cash flow used in operating activities during the nine months ended September 30, 2014 was approximately \$5.1 million, attributable to our net loss of approximately \$3.7 million and change in operating assets and liabilities of \$3.3 million of which net inventories was a change of approximately \$1.9 million offset by our net non-cash expenses of \$1.6 million. Cash flow provided by operating activities during the nine months ended September 30, 2013 was approximately \$0.1 million, attributable to our net non-cash expenses of \$5.8 million offset by our net loss of approximately \$5.4 million and change in operating assets and liabilities of \$0.3 million.

Cash provided by investing activities during the nine months ended September 30, 2014 was approximately \$4.7 million of which net short-term investments proceeds were approximately \$5.8 million offset primarily by equipment purchases of approximately \$1.0 million. Presently, we have committed approximately \$0.5 million for capital expenditures for the balance of 2014. During the nine months ended September 30, 2013 approximately \$0.8 million was used to purchase equipment and was offset by net short-term investments proceeds of \$0.8 million.

Cash provided by financing activities during the nine months ended September 30, 2014 was approximately \$1.1 million from option and warrant exercises as compared to \$0.3 million related to option exercises during the nine month period ended September 30, 2013.

Credit Facility

At September 30, 2014, we had a credit facility with Access Business Finance, LLC (“Access”) that provides for up to a maximum amount of \$3 million based on a borrowing base equivalent of 75% of eligible accounts receivable. The interest on the credit facility is equal to the Prime Rate plus 4% but may not be less than 7.25% with a minimum monthly interest payment of \$1 thousand. The credit facility will automatically renew on September 1, 2015 for a one year term unless written notice is provided. We did not draw on our credit facility during the nine months ended September 30, 2014 or at any time since its inception in September 2010 and there is no outstanding balance.

The credit facility contains the customary representations and warranties as well as affirmative and negative covenants. We were in compliance with all debt covenants as of September 30, 2014.

Our cash needs to fund our operations and investment requirements over the next twelve months may be more than our current cash on hand, investments and the cash we anticipate generating from operations. We may not require additional funds over the next twelve months. If we do require additional funds, we believe we can raise sufficient funds. However, if we are unable to obtain sufficient funds, we may have to reduce the size of our organization and/or be forced to reduce and/or curtail our production and operations, all of which could have a material adverse impact on our business prospects.

Off-Balance Sheet Arrangements

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Market rate risk

We are exposed to market risk related to changes in interest rates.

Interest rate risk

We hold our cash in cash and cash equivalents and certificates of deposits. We do not hold derivative financial instruments or equity securities. At September 30, 2014, we have not drawn on our revolving line of credit and therefore do not have any related interest rate risk. A change in interest rates would not have had a material effect on our consolidated financial position, results of operations, or cash flows in the three and nine months ended September 30, 2014.

Table of Contents

Foreign currency exchange rate risk

We do not have any material foreign currency exchange rate risk.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q.

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.

There were no changes in our internal controls over financial reporting during the fiscal quarter ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

None.

ITEM 1A. Risk Factors

In addition to other information set forth in this Report, you should carefully consider the risk factors previously disclosed in “Item 1A to Part 1” of our Annual Report on Form 10-K for the year ended December 31, 2013. There were no material changes from the risk factors during the nine months ended September 30, 2014.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Issuer Repurchases of Equity Securities

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

None.

ITEM 5. Other Information

None.

Table of Contents

ITEM 6. Exhibits

| | |
|-------------|--|
| <u>31.1</u> | <u>Certification by Chief Executive Officer pursuant to Sarbanes Oxley Section 302 (1)</u> |
| <u>31.2</u> | <u>Certification by Chief Financial Officer pursuant to Sarbanes Oxley Section 302 (1)</u> |
| <u>32.1</u> | <u>Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350 (1)</u> |
| <u>32.2</u> | <u>Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (1)</u> |
| 101.INS | XBRL Instance Document (2) |
| 101.SCH | XBRL Taxonomy Extension Schema Document (2) |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document (2) |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document (2) |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document (2) |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document (2) |

(1) Filed herewith.

(2) Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 13th day of November 2014.

eMAGIN CORPORATION

By: /s/ Andrew G. Sculley
Andrew G. Sculley
Chief Executive Officer
Principal Executive Officer

By: /s/ Paul Campbell
Paul Campbell
Chief Financial Officer
Principal Accounting and Financial Officer